These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2025495)

  • 21. Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer.
    Taylor CW; Alberts DS; Peng YM; McCloskey TM; Matzner M; Roe DJ; Plezia PM; Grindey GB; Hamilton M; Seitz D
    J Natl Cancer Inst; 1992 Dec; 84(23):1798-802. PubMed ID: 1433369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor diarylsulfonylureas: novel agents with unfulfilled promise.
    Houghton PJ; Houghton JA
    Invest New Drugs; 1996; 14(3):271-80. PubMed ID: 8958182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo.
    Rockwell S
    J Natl Cancer Inst; 1983 Oct; 71(4):765-71. PubMed ID: 6413743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary studies with a new hypoxia-selective cytotoxin, KS119W, in vitro and in vivo.
    Kim EY; Liu Y; Akintujoye OM; Shyam K; Grove TA; Sartorelli AC; Rockwell S
    Radiat Res; 2012 Sep; 178(3):126-37. PubMed ID: 22862779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Failure of 5-thio-D-glucose to alter cell survival in irradiated or unirradiated EMT6 tumors.
    Rockwell S; Schulz RJ
    Radiat Res; 1984 Dec; 100(3):527-35. PubMed ID: 6505142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of extracellular pH on the accumulation and cytotoxicity of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea in human cell lines.
    Sosinski J; Chapin C; Thakar JH; Houghton PJ
    Cancer Commun; 1991; 3(12):373-81. PubMed ID: 16296003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for mitochondrial localization of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea in human colon adenocarcinoma cells.
    Houghton PJ; Bailey FC; Houghton JA; Murti KG; Howbert JJ; Grindey GB
    Cancer Res; 1990 Feb; 50(3):664-8. PubMed ID: 2297707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice.
    Rockwell S; Kelley M
    Radiat Oncol Investig; 1998; 6(5):199-208. PubMed ID: 9822166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
    Teicher BA; Holden SA; Khandakar V; Herman TS
    J Cancer Res Clin Oncol; 1993; 119(11):645-51. PubMed ID: 8394365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of changes in oxygen tension, pH, and glucose concentration on the response to CCNU of EMT6 mouse tumor monolayer cells and multicellular spheroids.
    Kwok TT; Twentyman PR
    Int J Radiat Oncol Biol Phys; 1988 Jun; 14(6):1221-9. PubMed ID: 3384723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin.
    Kirichenko AV; Rich TA; Newman RA; Travis EL
    Cancer Res; 1997 May; 57(10):1929-33. PubMed ID: 9157987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of pH on the cytotoxicity of cisplatin in EMT6 mouse mammary tumor cells.
    Laurencot CM; Kennedy KA
    Oncol Res; 1995; 7(7-8):371-9. PubMed ID: 8747600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination.
    Teicher BA; Holden SA; Eder JP; Herman TS; Antman KH; Frei E
    Semin Oncol; 1990 Feb; 17(1 Suppl 3):18-32. PubMed ID: 2106164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of hyperthermia on the activity of 1-[(4'-hydroxy-2'-butenoxy)methyl]-2-nitroimidazole, which is cytotoxic to hypoxic cells.
    Kusumoto T; Maehara Y; Emi Y; Sakaguchi Y; Baba H; Sakaguchi M; Sugimachi K
    Cancer Chemother Pharmacol; 1993; 31(6):455-8. PubMed ID: 8453684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of mitomycin C and porfiromycin on exponentially growing and plateau phase cultures.
    Rockwell S; Hughes CS
    Cell Prolif; 1994 Mar; 27(3):153-63. PubMed ID: 10465006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the methemoglobinemia associated with sulofenur.
    Molthrop DC; Wheeler RH; Hall KM; Prchal JT
    Invest New Drugs; 1994; 12(2):99-102. PubMed ID: 7860238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.
    Aft RL; Lewis JS; Zhang F; Kim J; Welch MJ
    Cancer Res; 2003 Sep; 63(17):5496-504. PubMed ID: 14500386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro.
    Rockwell S; Donnelly ET; Liu Y; Tang LQ
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):536-41. PubMed ID: 12243833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical studies of porfiromycin as an adjunct to radiotherapy.
    Rockwell S; Keyes SR; Sartorelli AC
    Radiat Res; 1988 Oct; 116(1):100-13. PubMed ID: 3186923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sulofenur cytotoxicity and changes in cytosolic calcium and mitochondrial membrane potential in human colon adenocarcinoma cell lines.
    Phelps PC; Jain PT; Berezesky IK; Boder GB; Trump BF
    Cancer Lett; 1995 Jan; 88(1):27-35. PubMed ID: 7850770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.